LiPlasome Pharma
 
UpdateWorking at LiPlasomeCorporate partnershipInvestorPress
 
Search  Search
LiPlasome Goals and Beliefs Targeted Lipid Technology LiPlasome Pipeline Future Potential Library About LiPlasome
 

Better and safer cancer therapeutics first in line

The combination of a protected blood transporting nanocarrier system and a tumor specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive and dynamic anticancer market, where drug delivery systems will gain increasing importance over the coming years.

Read more

Update
 

LiPlasome Pharma welcomes Charlotte Vermehren as DMPK Manager

Charlotte Vermehren joined LiPlasome as DMPK...

LiPlasome Pharma welcomes Mogens Winkel Madsen as Chief Scientific Officer

Dr. Madsen has more than 20 years experience within drug discovery and cancer research...

Creating a successful business with a new visual identity

The upcoming biotech company LiPlasome Pharma A/S is launching a new visual identity...

Current Progress

LiPlasome Pharma has successfully concluded part of its preclinical studies and demonstrated proof of principle of the tumor activated and integrated prod...

View all

View LiPlasome eventcalender

The Magic Bullet scientific theater

Open Positions at LiPlasome

LiPlasome Pharma A/S l Technical University of Denmark, Building 207 l DK-2800 Lyngby l Tel: + 45 45 25 24 00

Sitemap | Privacy Policy